Abstract
Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.
Keywords: Platelet, aggregation, thrombosis, aspirin, clopidogrel, myocardial infarction, stroke
Current Pharmaceutical Design
Title: Platelets and Vascular Risk: An Option for Treatment
Volume: 13 Issue: 16
Author(s): I. A. Jagroop, A. I. Kakafika and D. P. Mikhailidis
Affiliation:
Keywords: Platelet, aggregation, thrombosis, aspirin, clopidogrel, myocardial infarction, stroke
Abstract: Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis.
Export Options
About this article
Cite this article as:
Jagroop A. I., Kakafika I. A. and Mikhailidis P. D., Platelets and Vascular Risk: An Option for Treatment, Current Pharmaceutical Design 2007; 13 (16) . https://dx.doi.org/10.2174/138161207780831383
DOI https://dx.doi.org/10.2174/138161207780831383 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peripheral Arterial Disease - The Forgotten Risk Factor
Vascular Disease Prevention (Discontinued) Evolution of Biomarker Guided Therapy for Heart Failure: Current Concepts and Trial Evidence
Current Cardiology Reviews Fullerenes for Cancer Diagnosis and Therapy: Preparation, Biological and Clinical Perspectives
Current Drug Metabolism Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Oxidative Stress on Progenitor and Stem Cells in Cardiovascular Diseases
Current Pharmaceutical Biotechnology New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Antidiabetic Oils
Current Diabetes Reviews Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Pharmacokinetic Interactions Between Herbal Medicines and Prescribed Drugs: Focus on Drug Metabolic Enzymes and Transporters
Current Drug Metabolism Patent Selections:
Current Regenerative Medicine (Discontinued) Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification
Current Pharmaceutical Design Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Subject Index To Volume 2
Current Cardiology Reviews Is Bilirubin a Marker of Vascular Disease and/or Cancer and is it a Potential Therapeutic Target?
Current Pharmaceutical Design Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and Oxidative Stress
Current Cardiology Reviews Mast Cells and Inflammatory Heart Disease: Potential Drug Targets
Cardiovascular & Hematological Disorders-Drug Targets Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets Multitarget Drugs of Plants Origin Acting on Alzheimer's Disease
Current Medicinal Chemistry